A non-invasive alternative to liver biopsy, now the standard method of diagnosing cirrhosis in hepatitis patients, proved very reliable in a national multi-center study including Henry Ford Hospital. The results of the study are good news for chronic hepatitis B and C sufferers who now often undergo repeated and potentially painful liver biopsies as part of their disease management.
Â
The focus of the research was the French-made FibroScan, which was being used in more than 70 countries worldwide when it received approval by the U.S. Food and Drug Administration in April.
Â
The study is being presented at the annual meeting of the American Association for the Study of Liver Diseases being held in Washington, D.C., Nov. 1-5.
Â
In liver biopsy, a sample of tissue is most often collected using a needle inserted through the skin and underlying tissue and into the liver. It is widely regarded as safe, but because it's invasive, carries risks ranging from pain and bleeding, to rare instances of death.
Â
FibroScan replaces liver biopsies with a quick and painless procedure similar to the familiar ultrasound tests long used to diagnose and track pregnancy, as well as internal disease.
Â
It's based on a technology called transient elastography, which measures liver "stiffness" to assess the degree of fibrosis scarring and guide ongoing treatment. The scan is performed as an outpatient procedure, taking only about 15 minutes, and providing immediate results on the degree of liver fibrosis.
Â
To confirm the accuracy of FibroScan already established by research studies in Europe and Asia the new U.S. research focused on 814 patients with chronic type B and C viral hepatitis.
Â
Each was examined using FibroScan followed by liver biopsy, and the results were compared according to several criteria.
Â
"What we found," says Stuart C. Gordon, MD, director of the Hepatology section at Henry Ford, who participated in the study, "confirms that FibroScan very accurately assesses for the presence of cirrhosis in patients with both types of chronic viral hepatitis."
Â
The study also noted that the device "exhibits excellent reproducibility," which makes it a "reasonable alternative" to liver biopsy.
Source: Henry Ford Hospital
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.